Could Parkinson’s One Day Be Prevented Before It Begins?

Experimental Australian drug produces encouraging results in people at high risk of developing Parkinson’s

A small Australian-linked clinical trial has produced results being described as extraordinarily encouraging — and it represents an important change in the way researchers are thinking about Parkinson’s.

Instead of waiting until someone has developed the characteristic movement symptoms of Parkinson’s and then treating those symptoms, researchers are investigating whether it may be possible to intervene years earlier — before Parkinson’s has even been diagnosed.

The experimental drug is called SNT-4728, developed by Australian biotechnology company Syntara.

And while it is far too early to say that scientists have found a drug that can prevent Parkinson’s, the results give us an intriguing glimpse of what the future of Parkinson’s prevention could potentially look like.

Why this study is different

Parkinson’s does not suddenly begin on the day someone receives their diagnosis.

Changes within the brain may have been developing for many years before the characteristic movement symptoms become obvious.

By the time those motor symptoms emerge, significant neurological changes may already have occurred.

That creates an enormous challenge:

How do we identify people earlier — and could we intervene before substantial damage has occurred?

This trial attempted to do exactly that.

Rather than recruiting people already diagnosed with Parkinson’s, researchers studied people with isolated REM sleep behaviour disorder, or iRBD.

What is REM sleep behaviour disorder?

During normal REM sleep — the stage in which much of our dreaming occurs — the brain temporarily prevents most of our muscles from moving.

People with REM sleep behaviour disorder can lose this normal protection and may physically act out their dreams — talking, shouting, punching, kicking or moving while asleep.

Importantly, iRBD can also be an early warning sign of neurological disease.

Parkinson’s UK reports that around 7 in 10 people with iRBD go on to be diagnosed with Parkinson’s within 15 years.

That makes this group extremely valuable to researchers.

It potentially provides a window into Parkinson’s before the disease reaches the stage at which we would normally diagnose it.

The study

The Phase 2 trial involved just 41 participants at research sites in Sydney and Oxford.

Thirty received SNT-4728 and the remainder received placebo. Participants took the treatment once daily for 12 weeks.

This was a randomised, double-blind, placebo-controlled study — an important feature because neither participants nor researchers assessing them knew who was receiving the experimental treatment.

The group was also particularly interesting biologically.

Among the participants:

• 95% had misfolded alpha-synuclein detected in their cerebrospinal fluid.
• 90% had reduced or absent sense of smell.
• The median age was 68.
• 93% were male.

Alpha-synuclein is especially important because abnormal accumulation of this protein is closely associated with Parkinson’s and related neurological disorders.

In other words, researchers weren’t simply studying people with a sleep disorder.

They had assembled a group showing several characteristics associated with increased risk of future neurodegenerative disease.

Result 1: Brain inflammation was reduced

The first results were released in July 2026.

Researchers used PET brain imaging to examine neuroinflammation.

After 12 weeks of treatment, they detected a statistically significant reduction in an inflammation-related imaging signal in the putamen in the SNT-4728 group.

Twenty of the 30 people receiving the drug showed a reduction from baseline.

The putamen is particularly interesting because it forms part of the brain circuitry involved in movement and is affected in Parkinson’s.

However, there is an important qualification.

The same statistically significant reduction was not demonstrated in all of the predefined brain regions examined, including the substantia nigra, caudate and occipital cortex.

So these results should not be interpreted as evidence that the drug simply “stopped inflammation throughout the Parkinson’s brain.”

Nevertheless, detecting a measurable biological change after only 12 weeks was encouraging.

And then came the next result.

Result 2: Movement improved

Further results released in October showed something particularly interesting.

Researchers assessed participants’ movement using a recognised clinician-assessed Parkinson’s motor scale.

People who had received SNT-4728 demonstrated an improvement in movement compared with those receiving placebo.

The placebo group, meanwhile, worsened.

Most intriguingly, the difference was statistically significant 12 weeks after participants had stopped taking the drug.

Think about the significance of that.

These weren’t people being treated for diagnosed Parkinson’s.

They were people considered at high risk of developing Parkinson’s and related neurological diseases.

They received the experimental treatment for just three months.

And a measurable difference in movement was still detectable three months after treatment stopped.

That is why researchers are paying attention.

What is SNT-4728 actually trying to do?

SNT-4728 targets two enzymes associated with inflammation: SSAO and MAO-B.

The theory being investigated is that excessive neuroinflammation may contribute to the processes that eventually damage brain cells.

Syntara therefore describes SNT-4728 as a neuro-targeted anti-inflammatory therapy.

This is fundamentally different from simply trying to replace dopamine once Parkinson’s symptoms have developed.

Researchers are attempting to influence a biological process that may be involved much earlier in the disease pathway.

And that leads to the really important question.

Has this drug been shown to prevent Parkinson’s?

No.

This is the most important caution around this story.

Despite headlines discussing the possibility of preventing Parkinson’s, this trial has not demonstrated that SNT-4728 prevents Parkinson’s disease.

The study was small — only 41 people.

Treatment lasted only 12 weeks.

And researchers have not yet shown that people receiving SNT-4728 are less likely to eventually develop Parkinson’s than people receiving placebo.

To establish that would require much larger and longer clinical trials.

Researchers would ultimately need to demonstrate that treatment significantly delays or prevents progression to clinically diagnosed Parkinson’s or another related neurodegenerative disease.

That evidence does not yet exist.

There were also no significant changes reported in participants’ sleep, thinking and memory, or quality-of-life assessments in this trial.

So we should be excited — but careful.

Why HEAL believes this research matters

The significance of this story goes beyond SNT-4728.

It represents a profound change in thinking about neurological disease.

For decades, the model has largely been:

Symptoms appear → diagnosis occurs → treatment begins.

The emerging model could eventually become:

Identify risk → detect early biological changes → intervene → delay or possibly prevent clinical disease.

That is a very different approach.

And it reflects one of the fundamental principles behind HEAL:

Prevention doesn’t begin when disease is diagnosed.

It begins much earlier.

Parkinson’s, dementia and other neurodegenerative conditions are extraordinarily complex. Some cases may never be preventable, and we must never suggest that someone who develops these diseases somehow failed to prevent them.

But research is increasingly allowing scientists to look further back into the disease process.

What happens 5 years before diagnosis?

What happens 10 years before?

Can we identify the earliest biological changes?

And, most importantly:

Can we do something about them?

SNT-4728 doesn’t yet give us that answer.

But this small trial suggests that intervening during this earlier window may be biologically possible.

That alone makes this research worth watching.

The HEAL Takeaway

This isn’t a cure for Parkinson’s.

And it isn’t yet a drug that has been proven to prevent Parkinson’s.

But it may represent something equally important: a change in direction.

Instead of asking only:

“How do we treat Parkinson’s once someone develops it?”

researchers are increasingly asking:

“Can we identify the disease process earlier and intervene before Parkinson’s fully develops?”

That is where prevention science becomes incredibly exciting.

The first SNT-4728 results showed a measurable reduction in an inflammation-related brain signal.

The latest results showed an improvement in clinician-assessed movement compared with placebo — remarkably, still evident 12 weeks after treatment stopped.

Now we need larger studies, longer follow-up and, ultimately, evidence that changing these early biological processes actually changes a person’s likelihood or timing of developing Parkinson’s.

Until then, this remains experimental.

But it is exactly the kind of research HEAL will continue to follow.

Because the future of neurological medicine may not only be about finding better treatments after diagnosis.

It may increasingly be about recognising risk, intervening earlier and preventing or delaying disease before it takes hold.

Small changes. Earlier action. Better information.

Healthy. Educated. Active. Living.

The HEAL Effect